Preparation and Evaluation of Inflammation Targeted Nano-micellar Formulation of Celecoxib
Celecoxib
DOI:
10.14235/bas.galenos.2018.2673
Publication Date:
2019-07-26T08:21:26Z
AUTHORS (8)
ABSTRACT
Objective: Celecoxib (CLX), brand named Celebrex, which belongs to non-steroidal anti-inflammatory drugs family, selectively inhibits the cytokine related cyclooxygenase-2 isoenzyme and thus, possesses less gastrointestinal side effects, have shown cause stroke, myocard infarction even death in some cases.In this study we aimed target inflammation site using CLX uploaded nano-micelles (nano-CLX) made of poly (lactic-co-glycolic) acid (PLGA) protect other tissues from its effects.Methods: was physically entrapped PLGA micelles w/o/w emulsion method, resulted obtaining mono-dispersed particles with 112 nm size.50 mg able carry 50 20 mL (2.5 mg/mL) encapsulation efficiency 85%.Rheumatoid arthritis model achieved by injection complete Freund's Adjuvant hint paw Wistar rats.Infected groups received oral intravenous (i.v.) Celebrex nano-CLX.Each group compared a healthy control receiving drug via same routes.The obtained serums sizes were studied for 6 hours 3 time periods.Results: Prostaglandin E2 tumor necrosis factor-α levels found be decreased longer period application nano-CLX i.v.Celebrex.Interleukin-1 (IL-1) IL-6 showed dramatic decrease at orally administered groups, showing accumulation these pro-inflammatory factors area. Conclusion:Based on hypothesis that ratio blood parameters is inversely proportional site, our nano-formulation targeted systemic flow better selective inhibition.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (3)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....